Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.47 |
| ▸ | NPC1 | O15118 | 6/20 | 0.47 |
| ▸ | GBA1 | P04062 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14009148 | 0.87 | POLB (0.41) | RAB9ANPC1GBA1POLBTDP1 | |
| SCHEMBL14009163 | 0.83 | ROCK1 (0.51) | RAB9ANPC1MAPTTP53SMN1; SMN2 | |
| SCHEMBL14009117 | 0.83 | NPC1 (0.52) | RAB9ANPC1TDP1MAPTTP53 | |
| SCHEMBL14009070 | 0.82 | RAB9A (0.51) | RAB9ANPC1MAPTKMT2AROCK1 | |
| SCHEMBL14609404 | 0.82 | ROCK1 (0.45) | RAB9ANPC1POLBMAPTSMN1; SMN2 | |
| SCHEMBL14009349 | 0.81 | ROCK1 (0.46) | RAB9ANPC1POLBMAPTTP53 | |
| SCHEMBL14009001 | 0.81 | KDM4E (0.53) | RAB9ANPC1POLBMAPTMEN1 | |
| SCHEMBL14009145 | 0.80 | NPC1 (0.55) | RAB9ANPC1GBA1POLBMAPT | |
| SCHEMBL14609432 | 0.80 | ROCK1 (0.45) | RAB9ANPC1POLBMAPTSMN1; SMN2 | |
| SCHEMBL14009209 | 0.80 | ESRRG (0.48) | MAPTTP53SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446195-B2 | High affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446195-B2 | High affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION (US) | 2008-11-04 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| WO-2007022258-A1 | NOVEL HIGH AFFINITY THIOPHENE-BASED AND FURAN-BASED KINASE LIGANDS | SCHERING CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | CDKL2, CDK2, CDKL1 | RAB9A 3846/4885NPC1 4547/4885GBA1 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.